• MIOCA
  • MIOCA
  • home_page_4
  • home_page 5
  • home page

WELCOME TO MIOCA

Established in 2011, the Michigan Ovarian Cancer Alliance strives to save the lives of women and girls by promoting the early detection of ovarian cancer and improved treatment outcomes.  MIOCA raises awareness of ovarian cancer, provides resources and support to survivors and their families, advocates both locally and federally, educates Michigan communities, and funds innovative ovarian cancer research.

MIOCA in the news

MIOCA Reaches $500,000 in Research Grants Awarded in Michigan

ANN ARBOR, MI - On World Ovarian Cancer Day, the Michigan Ovarian Cancer Alliance (MIOCA) announces an important milestone in its effort to save lives. Since it started giving grants in 2014, MIOCA has now awarded over a half-million dollars to researchers in Michigan who are finding new ways to improve the early detection and treatment of ovarian cancer.

“MIOCA is pleased to announce three 2019 Geri Fournier Ovarian Cancer Research Award winners, who will each receive $50,000 as part of our efforts to forward ovarian cancer research in our state.” said MIOCA Founder and President, Pam Dahlmann. The Award, named for the Founders’ mother who helped establish MIOCA before her death from ovarian cancer in 2011, was created to recognize the critical research happening right here, in our state, which is often underfunded. “Each and every research project we fund has the potential to result in improved understanding of the disease that will hopefully transform lives for women across Michigan and beyond.”

The State of Michigan is fortunate to have several of the nations’ top ovarian cancer researchers, and this year’s winners represent three institutions who are leading the way in ovarian cancer research. This year’s winners are:

• Rebecca Liu, M.D, Saint Joseph Mercy Health System,
  University of Michigan Rogel Cancer Center
  Michigan Cancer Research Consortium 
  "EASE: Education, Alliance, Solace, and Empowerment for
  Ovarian Cancer Patients."

• Nouri Neamati, Ph.D., University of Michigan College of Pharmacy, and 
  Karen McLean, M.D., Ph.D., University of Michigan Medical School,
  University of Michigan Rogel Cancer Center 
  "Development of STAT3 inhibitors for the treatment of ovarian cancer."

• John Risinger, Ph.D., Michigan State University
  College of Human Medicine 
  "PARP inhibition and non-BRCA DNA damage repair mutation."

For the entire Press Release, click here.